Navigation Links
Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007)

ith mean reductions of 19.7 mm Hg systolic/12.7 mm Hg diastolic for amlodipine 10 mg alone (placebo= 4.8/3.1 mm Hg). When compared to amlodipine 10 mg alone, amlodipine 10 mg/day plus olmesartan 40 mg/day resulted in a 53 percent greater reduction in systolic blood pressure. Amlodipine combined with olmesartan provides two complimentary mechanisms of action to lower blood pressure: calcium channel blockade with amlodipine and angiotensin receptor blockade with olmesartan.

The AE profile for each of the combinations was similar in nature to the monotherapy components. Most reported treatment-emergent adverse events across all treatment groups were considered mild in severity.

Hypertension, also known as high blood pressure, affects approximately 72 million people in the United States and approximately one billion worldwide. It is often difficult to control, and of those diagnosed with high blood pressure, 64.9 percent do not have the condition under control.1

Study Design

The study was a Phase III, 8-week, randomized, double-blind, placebo-controlled, parallel-group, factorial study in 1,940 patients with mild to severe hypertension defined as seated diastolic BP between ? 95 mm Hg and ? 120 mm Hg. The purpose of the study was to determine if co-administration of amlodipine 5-10 mg/day and olmesartan 10-20-40 mg/day had a significant benefit vs. its respective monotherapy components. Primary and one of the secondary endpoints were mean change from baseline in seated diastolic and seated systolic blood pressure at week 8, respectively.






Page: 1 2 3 4

Related medicine technology :

1. Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
2. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
(Date:8/31/2015)... TWINSBURG, Ohio , Aug. 31, 2015 /PRNewswire/ ... and applications, has acquired MACTek Corporation, a leading ... part of Pepperl+Fuchs, strategy to further extend its ... the WirelessHART market.    "We are ... to our existing portfolio," said Jim Bolin ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
(Date:8/31/2015)... , August 31, 2015 ... the global cardiovascular monitoring and diagnostic devices market ... predicted to reach a value of approximately US$7.0 ... 9.7% between 2013 and 2019. The title of ... Market (ECG, Holter Monitors, Event Monitors, Cardiovascular Diagnostic ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5
(Date:8/31/2015)... ... ... Dr. Stewart Shofner of Shofner Vision Center explains what causes lazy ... eye examination can diagnose amblyopia. According to the National Eye Institute (NEI), ... to 3 out of every 100 children. , Dr. Shofner adds, “unless amblyopia ...
(Date:8/31/2015)... ... August 31, 2015 , ... Nine innovative healthcare companies (listed ... in Healthcare(SM) Awards Event , on October 21, 2015, in Long Beach. The ... organizations and individuals who are dramatically reducing the cost of quality healthcare. , ...
(Date:8/31/2015)... ... 2015 , ... Finnleo is pleased to announce another in a ... of extensive engineering and design of our newest sauna model, the Terrace combines high ... offered at a very attractive price-point. , Before outdoor saunas were a dream ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... and accessible primary care, is enhancing its existing presence in Tennessee with the ... The location is the company’s second in Knoxville, sixteenth in Tennessee, and 148th ...
(Date:8/31/2015)... New York (PRWEB) , ... August 31, 2015 , ... ... autumn, when play-offs and the World Series will dominate the sports world. Fans desire ... and eventually advance to the final series. For children, especially those who are too ...
Breaking Medicine News(10 mins):Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2
... illusion; ridiculous, says former star major league pitcher , FRIDAY, ... the pitcher,s hand. In less than a second, it curves ... , The curveball, when thrown correctly, is one of baseball,s ... and not so great have sworn that the ball seems ...
... FRANCISCO, Calif., Oct. 30 Anesiva, Inc. (Nasdaq: ANSV ... Stockholders will be held on December 3, 2009 at 9:00 ... Francisco, California. Stockholders of record at the close of ... at the 2009 Annual Meeting of Stockholders. The definitive ...
... (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, ... Tablets, at a major psychiatric medical meeting today. ... the change from baseline on the oppositional subscale of ... in patients ages 6 to 12 with a primary ...
... around right after procedure cuts conception rate, study found ... lie flat for 15 minutes after being artificially inseminated ... suggests. , "Allowing women treated for subfertility with IUI ... a 50 percent higher chance at conceiving," said Inge ...
... ... joined the crusade to better our environment by offering green printing services and eco-friendly ... information for the company,s custom labels offering. , ... Fort Scott, KS (PRWEB) October 30, 2009 --, , ...
... infants, studies show , FRIDAY, Oct. 30 (HealthDay ... who should get H1N1 swine flu and seasonal flu ... vaccination for moms-to-be and their babies. , Bigger, healthier ... top the findings, which are to be presented this ...
Cached Medicine News:Health News:Scientist Throws Curve Into Breaking-Ball Debate 2Health News:Scientist Throws Curve Into Breaking-Ball Debate 3Health News:Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 2Health News:Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 3Health News:INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale 2Health News:INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale 3Health News:Lying Still Raises Artificial Insemination Success 2Health News:Lying Still Raises Artificial Insemination Success 3Health News:My1Stop.com Launches New Custom Labels Solutions Making Pricing and Ordering Faster and Easier 2Health News:Flu Shot in Pregnancy Protects Baby 2Health News:Flu Shot in Pregnancy Protects Baby 3
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
The HT-PB is a implantable bipolar tined permanent pacing lead for stimulation of the ventricle....
... Flextend lead is a ... with an extendable/retractable active-fixation ... design offers various lead ... implantation in the atrium ...
The RU is a low profile implantable bipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
Medicine Products: